| am wondering how this might all fit together.

Do you have a few minutes to speak with me about this? I’m at{_®)@, and
I'd greatly value your advice. Just let me know when you might be able to call, so
that I’m notin the midst of a Zoom meeting.

Best, Francis

From: Stoffels, Paul (JCUS|[[ >

Sent: Tuesday, March 24, 2020 12:58 PM

To: Collins, Francis (NIH/OD) [EI~ CO)

Subject: Re: Reaching out about partnerships and COVID-19

Absolutely worthwile. | will write an email in the next hours.

CO.
Paul

Verstuurd vanaf mijn iPhone

Op 24 mrt. 2020 om 17:55 heeft Collins, Francis (NIH/OD) [E]
C__@)(@}> het volgende geschreven:

Hey again Paul,

Really hoping to hear your thoughts on this proposal. FDA is highly
enthusiastic. Dolsten isin. Other pharma R&D Chiefs that would be
most helpful? Jay Bradner? John Reed? Roger Perlmutter?

Thanks, Francis

From: Collins, Francis (NIH/OD) [E]
Sent: Monday, March 23, 2020 5:17 PM

To: Stoffels, Paull _ Bi >

Subject: Reaching out about partnerships and COVID-19
Dear Paul,

I've been thinking that this is a time where we ought to have the best and
brightest minds from industry, NIH, academia, and FDA around the same
table to identify ways that we can move the coronavirus agenda forward to
life-saving products as quickly as possible. Several pharmas and biotechs have
been reaching out to NIH to identify viral assays and animal models that can

NIH-000215
